IP Library Granted Patent US 8,192,929
Granted Patent B2
US 8,192,929 · App. 11/792,426 · Granted Jun 5, 2012

Assay system for monitoring the effects of genetically engineered cells to alter function of a synctium

Assignees: The Trustees of Columbia University in the City of New York; The Research Foundation of State University of New York
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,192,929
App. No.
11/792,426
Granted
Jun 5, 2012
Kind
B2
Abstract

This invention provides methods for determining the ability of a gene construct to alter the rhythm and contractility of a syncytial cell. Furthermore, this invention provides methods for constructing a gene construct capable of altering the rhythm or contractility of a syncytial cell. Finally, this invention provides a method for constructing a gene construct capable of coupling to a syncytial cell.

Claims (43)

1. A method comprising:

(i) providing a first and a second genetically modified cell that are either both cardiomyocytes or both mesenchymal stem cells (MSCs) comprising a nucleic acid construct, wherein the construct in the first cell comprises a gene that is expressed by the first cell, and the construct in the second cell does not comprise the gene;

(ii) providing a first and a second cardiac syncytial cell;

(iii) determining a baseline rhythm for the first and second cardiac syncytial cells in vitro;

(iv) contacting the first cardiac syncytial cell with the first cell of step (i) and contacting the second cardiac syncytial cell with the second cell of step (i) in vitro;

(v) determining the rhythm of the first and second cardiac syncytial cells after the contacting step (iv) in vitro; and

(vi) identifying the first cell of step (i) as a cell that alters rhythm of a cardiac syncytial cell if the rhythm of the first cardiac syncytial cell determined in step (v) differs from its baseline rhythm determined in step (iii), and the rhythm of the second cardiac syncytial cell determined in step (v) does not differ from its baseline rhythm determined in step (iii).

2. The method of claim 1 , wherein the gene is a gene encoding a hyperpolarization-activated, cyclic nucleotide-gated 2 (HCN2) channel.

3. The method of claim 1 , wherein rhythm is determined by photodiode detection of dye administered to the first and second cardiac syncytial cells.

4. The method of claim 3 , wherein the dye is a Ca-sensitive dye.

5. The method of claim 4 , wherein the Ca-sensitive dye is fluo-3.

6. The method of claim 3 , wherein the dye is a voltage sensitive dye.

7. The method of claim 1 , wherein rhythm is determined by edge detection in said first and second cardiac syncytial cells.

8. The method of claim 1 , wherein rhythm is determined with electrodes embedded in a test well.

9. The method of claim 8 , wherein the electrodes comprise one 150×30 micrometer diameter stimulating electrode and one 30 micrometer electrode.

10. The method of claim 9 , wherein the testing well has an inner diameter of at least 3 mm by 3 mm.

11. The method of claim 1 , wherein rhythm is determined with a glass patch electrode in a testing well.

12. The method of claim 11 , wherein the testing well has an inner diameter of at least 3 mm by 3 mm.

13. A method comprising:

(i) providing a first and a second genetically modified cell that are either both cardiomyocytes or both mesenchymal stem cells (MSCs) comprising a nucleic acid construct, wherein the construct in the first cell comprises a gene that is expressed by the first cell, and the construct in the second cell does not comprise the gene

(ii) providing a first and second cardiac syncytial cell;

(iii) determining a baseline contractility for the first and second cardiac syncytial cells in vitro;

(iv) contacting the first cardiac syncytial cell with the first cell of step (i) and contacting the second cardiac syncytial cell with the second cell of step (i) in vitro;

(v) determining the contractility of the first and second cardiac syncytial cells after the containing step (iv) in vitro; and

(vi) identifying the first cell of step (i) as a cell that alters the contractility of a cardiac syncytial cell if the contractility of the first cardiac syncytial cell determined in step (v) differs from its baseline contractility determined in step (iii), and the contractility of the second cardiac syncytial cell determined in step (v) does not differ from its baseline contractility determined in step (iii).

14. The method of claim 13 , wherein the gene is a gene encoding a hyperpolarization-activated, cyclic nucleotide-gated 2 (HCN2) channel.

15. A method comprising:

(i) providing in vitro a cardiac syncytial cell and a genetically modified cell that is either a cardiomyocyte or a mesenchymal stem cell (MSC) comprising a nucleic acid construct comprising a gene that is expressed by the genetically modified cell,

(ii) determining baseline rhythm of the cardiac syncytial cell in vitro;

(iii) contacting the cardiac syncytial cell with the genetically modified cell in vitro;

(iv) determining the rhythm of the cardiac syncytial cell in vitro following the contacting step of (iii); and

(v) comparing the baseline rhythm of step (ii) to the rhythm of step (iv), wherein the coupling of the cardiac syncytial cell and the genetically modified cell is indicated when the rhythm of step (ii) differs from the rhythm of step (iv).

16. The method of claim 15 , wherein the gene is a gene encoding a hyperpolarization-activated, cyclic nucleotide-gated 2 (HCN2) channel.

17. The method of claim 15 , wherein rhythm is determined by photodiode detection of dye administered to the first and second cardiac syncytial cells.

18. The method of claim 17 , wherein the dye is a Ca-sensitive dye.

19. The method of claim 18 , wherein the Ca-sensitive dye is fluo-3.

20. The method of claim 17 , wherein the dye is a voltage sensitive dye.

21. The method of claim 15 , wherein rhythm is determined by edge detection in said first and second cardiac syncytial cells.

22. The method of claim 15 , wherein rhythm is determined with electrodes embedded in a test well.

23. The method of claim 22 , wherein the electrodes comprise one 150×30 micrometer diameter stimulating electrode and one 30 micrometer diameter electrode.

24. The method of claim 23 , wherein the testing well has an inner diameter of at least 3 mm by 3 mm.

25. The method of claim 15 , wherein rhythm is determined with a glass patch electrode in a testing well.

26. The method of claim 25 , wherein the testing well has an inner diameter of at least 3 mm by 3 mm.

Assignments (3)
CONFIRMATORY LICENSE Recorded Jul 6, 2012
From: COLUMBIA UNIV NEW YORK MORNINGSIDE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 028503/0401 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 8, 2009
From: ROSEN, MICHAEL R.; ROBINSON, RICHARD B.
To: THE CITY OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
Reel/Frame 023618/0755 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 8, 2009
From: BRINK, PETER R.; COHEN, IRA S.
To: THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
Reel/Frame 023618/0883 →
Continuity (3)
Provisional Application 60589416 · Jul 19, 2004
Related Publication 20100068699A1 · Mar 18, 2010
Related Publication 20120028241A2 · Feb 2, 2012